# Liquid Mine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liquid-mine

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.liquidmine.co.jp/
- Total disclosed funding: $0.8M
- Latest round: Series B (Feb 1, 2023)
- Investors on record: 3

## About

Established in 2019 and based in Tokyo, Japan, Liquid Mine Inc. was formerly a member of The Institute of Medical Science, The University of Tokyo (IMSUT) back in 2015. Ever since, the company has switched to focus on the research work revolving genetic analysis. In 2017, the company developed MyRD, a medical information system, to conduct clinical trials and patient health inspection at multiple medical facilities. In May 2025, Liquid Mine, Inc. raised an undisclosed amount in venture funding from new investor Umusun Lab.

The company's main businesses include the development and sale of various medical testing programs, genetic analysis testing, pathological examination, as well as the research, development, manufacture and sale of in-vitro diagnostic drugs. The company generates revenues mainly from distributing tailor-made test drugs, Liquid Biopsy, for patients. Combined with the genetic analysis technique, the test drug is able to grasp the decrease number of diseased cells, and the number of remaining and recurring diseased cells. By analyzing each patient’s genetic mutations, the company offers precision medicine that is tailor-made to the treatment of each patient.

The company plans to use the May 2025 funding to continue the development of its gene analysis technology.

## Funding rounds

- Series B, Feb 1, 2023, $0.8M — Incubate Fund, aSTART, Gemseki Inc.

## Investors

- Incubate Fund (https://capitalatlas.ai/funds/incubate-fund) — Series B
- aSTART (https://capitalatlas.ai/funds/astart) — Series B
- Gemseki Inc. — Series B